Work

Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies

Year: 2005

Type: article

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2005.14.415

Authors: Patricia M. LoRusso, Alex A. Adjei, Mary Varterasian, Shirish Gadgeel, Joel Reid, David Y. Mitchell, Lorelei Hanson, Pamela DeLuca, Laura Bruzek, Jill Piens, Peggy Asbury, Keri Van Becelaere, Roman Herrera, Judith Sebolt-Leopold, Mark B. Meyer

Institutions: Mayo Clinic, Pfizer (United States), The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2156509877

FWCI: 12.09

Cites: 20

Cited by: 401

Related to: 10